Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 mars 2020 09h00 HE | Source: NLS Pharmaceutics

NLS Pharmaceutics Ltd. (NLS) Files Registration Statement for a Proposed Initial Public Offering

STANS, Switzerland, March 02, 2020 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
30 sept. 2019 10h00 HE | Source: NLS Pharmaceutics

NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio

STANS, Switzerland, Sept. 30, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
03 sept. 2019 08h00 HE | Source: NLS Pharmaceutics

NLS Announces Appointment of Industry Veteran Dr. Sandy Eisen as Chief Medical Officer

STANS, Switzerland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases, including...
13 août 2019 13h04 HE | Source: NLS Pharmaceutics

NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity

STANS, Switzerland, Aug. 13, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
03 juil. 2019 09h00 HE | Source: NLS Pharmaceutics

NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio

STANS, Switzerland, July 03, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments for the Central Nervous System (CNS) in...
19 mars 2019 16h05 HE | Source: NLS Pharmaceutics

NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®

STANS, Switzerland, March 19, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder...
21 févr. 2019 08h00 HE | Source: NLS-1 Pharma AG

NLS-1 Pharma and Eurofarma Enter to an Exclusive Licensing Agreement to Develop and Commercialize Nolazol® for the Treatment of ADHD in Latin America

STANS, Switzerland, Feb. 21, 2019 (GLOBE NEWSWIRE) -- NLS-1 Pharma (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and...